Medical News Hour

Reverse Medical Corporation announced today that it has received US Food and Drug Administration (FDA) conditional approval to begin a neurothrombectomy IDE study for its ReStore™ Microcatheter at twenty US centers. The study is planned to begin enrollment in US and European hospitals following investigating study center Institutional Review Board (IRB) approvals.

Link:

Reverse Medical Corporation Receives FDA IDE Clinical Study Approval For The ReStoreTM Microcatheter

Related posts:

1. Centralized Review Process Markedly Expedites Approval Of Cancer Clinical Trials
2. MorphoSys Receives Regulatory Approval To Start Phase 1b/2a Clinical Trial For MOR103 Program
3. APP Pharmaceuticals Receives Approval For Deferoxamine Mesylate For Injection, USP
4. APP Pharmaceuticals Receives Approval For The First Generic Chlorothiazide Sodium For Injection, USP
5. Teva Receives Final Approval For Generic Prevacid(R) Delayed-Release Capsules